NCT01725542View on ClinicalTrials.gov

Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders

PHASE2CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions

HCV-HIV Co-Infection

Interventions

DRUG

Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a

Trial Locations (1)

Unknown

All the Regions of the Country (33 Centers)

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT01725542 - Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders | Biotech Hunter | Biotech Hunter